Drug Repurposing of Metabolic Agents in Malignant Glioma by Seliger, Corinna & Hau, Peter
 International Journal of 
Molecular Sciences
Review
Drug Repurposing of Metabolic Agents in
Malignant Glioma
Corinna Seliger * and Peter Hau
Department of Neurology and Wilhelm Sander-NeuroOncology Unit, University Hospital Regensburg,
93053 Regensburg, Germany; peter.hau@ukr.de
* Correspondence: corinna.seliger@ukr.de; Tel.: +49-941-941-8464; Fax: +49-941-941-3295
Received: 15 August 2018; Accepted: 11 September 2018; Published: 14 September 2018


Abstract: Gliomas are highly invasive brain tumors with short patient survival. One major pathogenic
factor is aberrant tumor metabolism, which may be targeted with different specific and unspecific
agents. Drug repurposing is of increasing interest in glioma research. Drugs interfering with the
patient’s metabolism may also influence glioma metabolism. In this review, we outline definitions
and methods for drug repurposing. Furthermore, we give insights into important candidates for
a metabolic drug repurposing, namely metformin, statins, non-steroidal anti-inflammatory drugs,
disulfiram and lonidamine. Advantages and pitfalls of drug repurposing will finally be discussed.
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1. Introduction
Gliomas are highly aggressive brain tumors with a poor patient prognosis [1]. They are classified
using a recently revised multi-layer classification according to their histopathological characteristics,
genetic markers and WHO grades I-IV, including information on the presence of a mutation in the
isocitrate dehydrogenase gene (IDH) [2]. Glioblastomas (GBMs) are WHO grade IV gliomas with
a high level of malignancy and are associated with a median overall survival ranging between 15 and
26 months for patients within clinical trials [3,4]. The standard of care for GBM includes postoperative
combined radio-chemotherapy followed by chemotherapy with temozolomide alone [3]; depending
on local practice-tumor-treating fields [5].
Patients without an IDH mutation [6], namely most patients with GBM, and patients
with no methylation of the methylguanine-methyl transferase (MGMT) gene [7] and without
a loss-of-heterozygosity at chromosome 1p19q (LOH 1p19q) [8] show worse clinical outcomes.
Other important prognostic factors include the clinical performance score, age, extent of resection,
comorbidities, primary and secondary therapies [3,9] and an early tumor progression [10] or persistent
hyperglycemia as an important metabolic factor [11,12].
Beyond the standard of care as listed above, clinical trials are exploring targeted therapies,
for instance, against the Vascular Endothelial Growth Factor (VEGF) [13], Epidermal Growth Factor [14]
or Platelet Derived Growth Factor (PDGF) or their receptors [15]. Whether response to a targeted
therapy can be predicted in vitro is still under discussion [16,17].
2. Tumor Metabolism and Glioma
The prognostic relevance of IDH mutations in glioma has drawn significant attention to tumor
metabolism as a potential therapeutic target in recent times [6]. Long ago, in the 1920s, Otto Warburg
already described the phenomenon of aerobic glycolysis in tumor cells [18]. According to the Warburg
hypothesis, tumor cells tend to use glycolysis rather than oxidative phosphorylation to meet their
energetic needs even in the presence of oxygen. Potential benefits for the tumor cells may be derived
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from the accumulation of intermediates for biosynthetic pathways, the faster provision of energy
equivalents, the reduction of reactive oxygen species or the independence from intact mitochondria [19].
In addition, the final product of glycolysis, lactate, may also serve as an important pathogenic
factor in glioma, for example by the activation of TGF-beta2 by thrombospondin [20] or by local
immunosuppression [21]. Therefore, the research of Otto Warburg and his followers opened the door
for a wide range of studies on the role of metabolic mechanisms and repurposing of metabolically
active drugs in the therapy of glioma and beyond.
3. Definition and Principle of Drug Repurposing
Labels drug repurposing and drug repositioning are frequently used synonymously and
definitions vary [22]. Both terms stand for the use of a drug for another indication rather than
the one it was primarily investigated or approved for. Underlying reasons may be that new molecular
findings allow for targeting by compounds that may already be part of drugs that are in clinical use for
other diseases. Prominent examples are sildenafil [23,24] which is now used for erectile dysfunction
and pulmonary hypertension, or thalidomide [25], which was initially used for sleeping disorders and
nausea frequently leading to birth defects, but is now again used for multiple myeloma and leprosy.
There are different approaches to identifying drugs that may also serve for another indication.
Pharmaco-epidemiological studies investigate the association between drug use and the incidence
or progression of several tumors, including gliomas. Large databases such as the Clinical Practice
Research Datalink (CPRD), a primary care database including over 8 million patients in the UK [26],
or large population-based databases such as in Denmark [27] are used for this purpose. Other authors
investigated pooled analyses of randomized clinical trials [28] or data collected within one or
several institutions [11,12]. Often, research hypotheses have been generated out of such publications.
However, epidemiological studies are often limited by the fact that they are retrospective in nature,
which may give rise to several biases such as selection bias, confounding by indication or recall
bias. Furthermore, in drug studies, immortal time biases, time-window biases, and time-lag biases
are of major concern [29]. In addition, the mere observation of an association between drug use and
incidence or progression of a tumor does not allow for the definition of biological effects or mechanisms.
However, those may be then investigated in experimental analyses.
Another approach to identifying drugs for drug repurposing is the in silico drug repositioning.
Thereby, bioinformatic algorithms serve to investigate the associations between drugs, targets
and diseases. Different databases help analyze drug-target interactions on the genomic
(NCBI Phenome-Genome Integrator [30], Genome-wide Association Studies Catalogue [31]) or
proteomic level (Human Protein Atlas [32], human proteome map [33], proteomics database [34],
UniProt Knowledgebase [35], canSAR protein annotation tool [36]) and in disease oriented databases
(GeneCards [37], MalaCards [38], DisGeNET [39]) or databases focused on molecular targets
(DrugBank [40], U.S. Federal Drug Administration Database and Drugs of New Indications
database [41]).
Finally, activity-based drug repurposing is also an approach to identify new medications out of
old drugs. In this case, actionable targets are detected for different diseases regardless of concurrent
structural information. For example, ALK inhibitors such as crizotinib or ceritinib are used for different
neoplasms with an over-activated ALK kinase (usually caused by an EML4-ALK rearrangement) such
as neuroblastoma, non-small-cell lung carcinoma or anaplastic large cell lymphoma [42].
4. Metabolic Drug Repurposing in Glioma
Metabolic drugs are also under study for drug repurposing and include medications that are
proposed to influence the whole patient’s lipid, protein or carbohydrate metabolism or only the
metabolism within the neoplasm itself. A multitude of approved agents are under investigation for
metabolic drug repurposing [43,44]. In this study, we will focus only on some of the most prominent
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candidates for a repurposing of metabolic drugs, namely on metformin, statins, non-steroidal
anti-inflammatory drugs, disulfiram, and lonidamine.
4.1. Metformin
Metformin is a frequently used drug for the treatment of type 2 diabetes [45]. In addition to its
known effects of lowering blood glucose, metformin was associated with a reduced risk of cancer [46].
Metformin was hypothesized to interfere with insulin-like growth factor signaling by lowering glucose
and insulin levels, but also to directly inhibit complex 1 of the respiratory chain in tumor cells with
subsequent activation of the adenosine monophosphate kinase (AMPK) and downstream inhibition of
the mammalian target of rapamycin (mTOR) [47]. Other mTOR inhibitors are also under investigation
as potential anti-glioma agents. There are currently over 30 of those medications in clinical trials
(www.clinicaltrials.gov).
Several groups including ours investigated possible antineoplastic effects of metformin on glioma
cells [48–51] and postulated inhibitory effects on glioma cell growth [48,52–54] and invasion [55],
and on induction of apoptotic [48,52,54] or autophagic [50] cell death. Metformin was not found
to inhibit transforming growth factor (TGF)-β2, as described for other entities [53], but a significant
inhibition of the STAT3 signaling pathway could be observed [56].
In a large case-control analysis within the clinical practice research datalink (CPRD), we found
that use of metformin was not significantly associated with a reduced risk of glioma (Odds Ratio
(OR) for ≥30 vs. 0 prescriptions = 0.72; 95% Confidence Interval (CI) = 0.38–1.39), but there was
a significant inverse association between having a history of diabetes and the incidence of glioma
(OR = 0.74; 95% CI = 0.60–0.93 [57]). Possible explanations for the fact that metformin did not have an
impact on glioma risk albeit significant effects on cell culture and tumor models may be the limited
sample size of diabetic glioma patients on metformin in that study or intensified doses of metformin
in laboratory investigations as compared to daily diabetes treatment. Many laboratory studies used
doses of metformin around 10 mM, whereas 10 µM have been measured in the brain of diabetic
patients [58]. Another possible explanation may be that metformin does not affect the development of
glioma, but may have an influence on survival after glioma diagnosis.
Several studies analyzed how use of metformin influences progression of diabetic glioma patients.
A small study based on 276 patients with GBM found a prolonged progression-free survival time
in diabetic patients with metformin, which could not be recapitulated in multivariate analysis [11].
In a larger study, metformin was one of the most important predictors for better survival among
988 diabetic patients with GBM [59]. Interestingly, we found in a large study on 1093 patients that use
of metformin was associated with improved Overall Survival (OS) and Progression Free Survival (PFS)
of diabetic patients with WHO grade III (HR for OS = 0.30; 95% CI = 0.11–0.81), but not WHO grade
IV glioma (HR = 0.83; 95% CI = 0.57–1.20) [60]. Patients with WHO grade III glioma have a higher
incidence of IDH-mutations compared to patients with primary GBM. Potentially, patients with
IDH-mutated gliomas are more susceptible to metformin due to a higher metabolic vulnerability [61].
Several randomized clinical trials evaluate the addition of metformin to adjuvant treatment of
glioma (NCT02496741, NCT02149459, NCT02040376, NCT02780024, NCT03243851, NCT03151772,
NCT01430351), and one trial is currently investigating the effect of metformin and chloroquine
on IDH-mutated solid tumors including gliomas [62]. So far, there are no published results from
clinical trials on metformin in glioma. Despite encouraging in vitro and also epidemiological data
for other tumor entities, available data from randomized clinical trials on metformin are mostly
disappointing [63–68], except for one study in non-small cell lung cancer [69], which explored the
addition of metformin to standard chemotherapy and showed a survival benefit.
4.2. Statins
Statins have also been proposed for drug repurposing studies, after being associated with
a reduced tumor-related mortality for various cancers [29]. Statins may impact gliomas by changes in
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the mevalonate pathway with subsequent modulations on the RAS-RAF-MEK-ERK [70] or Akt [71]
signaling pathways.
Different studies found significant or non-significant inverse associations between statin use
and the risk of glioma [72,73]. Among those, we also found a non-significantly decreased risk
of glioma among patients with long-term use of statins in a case-control analysis of 2469 cases
and 24,690 controls (OR for ≥90 prescriptions = 0.75; 95% CI = 0.48–1.17). However, we did not
observe a trend for a decreasing risk of glioma with increasing statin prescriptions (p-value for
trend = 0.979) [74]. In a U.S. study based on 284 patients with GBM, preoperative statin use did not
influence patient survival [75]. In contrast, a study from Denmark found a borderline significantly
reduced mortality among 339 glioma patients when treated with statins (HR = 0.79; 95% CI = 0.63–1.00)
with propensity score matching for age, gender, year of diagnosis and comorbidities [76].
There are two clinical trials that investigate if statin use improves standard therapy for glioma.
One phase I trial studies the maximum tolerated dose, toxicity and safety of the combined use
of fluvastatin and celecoxib in patients with optico-chiasmatic low-grade glioma and relapsed
or refractory high-grade glioma localized outside the brainstem in children or young adults
(NCT02115074). Another study explored the efficacy and safety of atorvastatin in combination
with radiotherapy and temozolomide in glioblastoma (NCT02029573). So far, in other malignancies,
clinical trials investigating statins as an adjunct to standard therapies mostly failed to show survival
benefits [77–80], and partly showed increased muscle toxicity [81].
4.3. Non-Steroidal Anti-Inflammatory Drugs (NSAID)
Non-steroidal anti-inflammatory drugs (NSAIDs) are mostly used as analgesics [82]. They may
also inhibit gliomas by cyclooxygenase-dependent and independent ways [83,84]. In a murine
glioma model, treatment with diclofenac led to a reduced lactate production, leading to a decreased
lactate-mediated immunosuppression [21]. We also showed in a comparative study with several
glioma cells that both diclofenac and ibuprofen inhibited cell proliferation and migration; however,
although both medications inhibited STAT3, only diclofenac reduced extracellular lactate, c-myc and
activity of lactate dehydrogenase (LDH)-A [85].
NSAIDs, especially selective COX-2 inhibitors, are frequently part of the metronomic regimen
in early clinical trials for glioma. Metronomic therapy stands for frequent and regular low-dosed
therapy with fixed schedules such as daily or weekly drug use [86]. Often, several drugs are combined
in metronomic therapy. The combination of low-dose temozolomide and celecoxib was proposed to
interfere with glioma progression through anti-angiogenic mechanisms, reducing tumor edema [87].
Survival analyses of glioma patients with metronomic therapy including COX-2 inhibitors showed
partly moderate positive results [88–91], or no influences on patient survival [92–94].
Although no significant results were found in several large studies investigating the association
between use of NSAIDS and the risk of glioma by us and others [95–97], a recent meta-analysis found
a decreasing risk of glioma with increasing NSAID use, including non-aspirin and aspirin-NSAIDs [98].
Survival of glioma patients after use of NSAIDs has not been thoroughly investigated so far, other than
the metronomic regimen. Only one pooled analysis analyzed the effect of daily aspirin intake on
long-term risk of death due to cancer and found a significantly reduced risk among patients with brain
cancer using daily aspirin at a minimum of 5 years (HR = 0.31; 95% CI = 0.11–0.89) [99]. In general,
epidemiological studies on NSAID use and glioma survival are limited by the fact that many NSAIDs
are sold over the counter, used on demand and that they are more frequently used with worsening
symptoms including headaches due to cerebral oedema.
In general, despite promising results in preclinical studies for different tumor types,
more randomized placebo-controlled clinical trials are needed to evaluate whether use of COX-2
inhibitors influences the survival of cancer patients [100].
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4.4. Disulfiram
Disulfiram, also known as antabuse, is usually used to treat alcohol substance abuse as an alcohol
aversion drug. After intake of disulfiram, patients experience flu-like symptoms when they drink
alcohol, because the drug inhibits the aldehyde dehydrogenase (ALDH) [101]. Disulfiram was also
found to inhibit glioma-initiating cells, even when they were insensitive to temozolomide [102].
A high-expression of ALDH1A1 was found to be associated with highly invasive tumor cells
and higher grades of malignancy [103]. In addition to the inhibition of ALDH, disulfiram was also
proposed to suppress the proteasome [104] and nuclear factor kappa B signaling [105]. Acetate is also
an important metabolite for the Krebs cycle and therefore treatment with disulfiram leads to energy
depletion [106]. Disulfiram was furthermore found to be a potent inhibitor of the pathophysiologically
important methylguanine-methyl-transferase, thereby increasing sensitivity to alkylating agents [107].
Enhancement of chemosensitivity was especially present when disulfiram was combined with
copper [104].
So far, there are no epidemiological studies investigating the association of disulfiram with the
risk of glioma or survival of glioma patients, potentially due to the low frequency of antabuse use in
daily clinical routine and the overall low frequency of glioma.
There are however several clinical trials exploring the addition of disulfiram to standard therapy.
A phase I study explored safety, maximum tolerated dose and preliminary efficacy of disulfiram in
combination with temozolomide. At maximum tolerated dose disulfiram exerted limited proteasome
inhibition on peripheral blood cells [108]. Disulfiram is also part of the CUSP-9 protocol (NCT02770378),
a metronomic regimen in recurrent glioblastoma (NCT02770378 [109]). Six other trials are currently
active and recruiting (NCT02678975, NCT03363659, NCT03151772, NCT02715609) or non-recruiting
(NCT01777919, NCT03034135) and one study is already completed (NCT01907165), but the results
are pending.
4.5. Ritonavir
Ritonavir is an HIV protease inhibitor, which interferes with the reproductive cycle of HIV.
It is used in the treatment of HIV and as a booster for other protease inhibitors in the treatment
of chronic hepatitis. Ritonavir was found to increase reliance of multiple myeloma cells to the
glutamine metabolism [110], possibly by inhibition of the glucose-transporter 4 (GLUT 4) [111].
In glioma, ritonavir was found to inhibit the chymotrypsin-like activity of the proteasome and to exert
cytostatic and cytotoxic effects on glioma cells, which may not be translated into in vivo models [112].
Other studies suggested that ritonavir inhibits several glucose transporters and thereby decreases
glucose consumption, lactate production and proliferation of glioma cells in vitro, which makes it also
an interesting candidate to combine with metformin [113]. In addition, ritonavir may interfere with
heat-shock protein 90 (HSP 90) in glioma cells [114] and exert interleukin 18-inhibiting activities [115].
Several groups tried to increase the activity of ritonavir as a single agent by combining it with other
agents such as temozolomide and aprepitant [116] or lopinavir [117]. The currently recruiting CUSP-9
trial (NCT02770378) combines ritonavir with aprepitant, artesunate, auranofin, captopril, celecoxib,
disulfiram, itraconazole, sertraline and continuous low dose temozolomide [109]. The only clinical
trial so far with published results is a phase II trial of ritonavir/lopinavir in patients with progressive
or recurrent high-grade gliomas that showed no survival benefit [117].
5. Discussion
Drug repurposing has emerged as an interesting field in glioma research. Compared to the
establishment of new drugs, drug repurposing is by far cheaper, as the drug has already been
developed, and faster, as trials can be readily started and a lot of data on side effects, tolerability
and other areas already exist. In addition, possible efficacy can be deduced from epidemiological
studies and from biological information on possible molecular targets. Major pitfalls however
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may be that epidemiological studies have more focus on the preventive effects of medications,
whereas prospective trials investigate drug therapy when the tumor is already established. In addition,
in vitro studies frequently use drug doses that outreach the doses used for established indications and
dose augmentation may be accompanied by new and severe side effects. This may explain that, so far,
drug repurposing has not led to any established standard of care in the treatment of glioma.
It is possible that umbrella trials, such as the NCT neuro Master Match-N2M2 trial (NCT03158389)
would be a good approach to investigate repurposed drugs in a clinical trial. Umbrella trials allow
us to investigate different drugs for different molecular alterations within one tumor entity within
the same clinical study, which makes it easier to identify subgroups of patients with a response to
specific drugs.
Another important aspect to discuss in the field of drug repurposing is the discrepancy between
promising epidemiological and laboratory findings and the mostly disappointing results of clinical
trials. Targeting of one specific metabolic alteration may lead to several rescue mechanisms,
which eventually leads to resistance to the metabolic drug. One approach to increase the efficacy of
single agents may be a combination of multiple agents in low doses hitting different targets, such as
in metronomic chemotherapy. Another approach would be to hit a growth sustaining element or
pathway along multiple points with a combinatory approach.
We argue for a more rational approach to drug repurposing that should integrate a deep
bioinformatic workup of large databases, adequate in vitro and in vivo models, rationale combinatory
approaches and tentative randomized Phase II trials to get a complete picture of the potential efficacy
of drug repurposing in malignant glioma.
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